DE19645974C1 - (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use - Google Patents
(Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and useInfo
- Publication number
- DE19645974C1 DE19645974C1 DE19645974A DE19645974A DE19645974C1 DE 19645974 C1 DE19645974 C1 DE 19645974C1 DE 19645974 A DE19645974 A DE 19645974A DE 19645974 A DE19645974 A DE 19645974A DE 19645974 C1 DE19645974 C1 DE 19645974C1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- thiazolidinone
- thioxo
- phosphonooxy
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Description
Es wurde nach einer Verbindung gesucht, die an einzelsträngige Nucleinsäure binden kann und sich von einem Naturstoff ableitet, der biochemisch relevant ist.A compound has been sought that can bind to single-stranded nucleic acid and is derived from a natural product that is biochemically relevant.
Es ist daher Aufgabe der Erfindung, ein Hilfsmittel für den Nachweis, und/oder die Analyse und/oder elektrophoretische Trennung von einzelsträngiger Nucleinsäure bereitzustellen. Darüber hinaus soll die Erfindung als Therapieprinzip von Krankheiten dienen, deren infektiöse Erreger sich im Wirt über Zwischenstufen mit einzelsträngiger Nucleinsäure vermehren. Die Aufgabe wird gelöst durch die Synthese von 3.It is therefore an object of the invention to be an aid for detection and / or analysis and / or to provide electrophoretic separation of single-stranded nucleic acid. About that In addition, the invention is intended to serve as a therapeutic principle for diseases, their infectious agents multiply in the host via intermediates with single-stranded nucleic acid. The task is solved by the synthesis of 3.
Bei der Substanz 3 handelt es sich um ein Derivat des Vitamin B6-Coenzymes Pyridoxal-5'-
phosphat 1. Es wird mit dem synthetischen Heterocyclus Rhodanin 2 (2-Thioxo-4-thiazolidinon)
in einer Knoevenagel-Kondensation umgesetzt.
Substance 3 is a derivative of the vitamin B 6 coenzyme pyridoxal-5'-phosphate 1. It is reacted with the synthetic heterocycle rhodanine 2 (2-thioxo-4-thiazolidinone) in a Knoevenagel condensation.
Die Verbindung 3 trägt den Namen (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4- pyridinyl]methylen]-2-thioxo-4-thiazolidinon, oder trivial benannt (Z)-5'-O-phosphono pyridoxylidenrhodanin. Der Rhodanin-Teil des Moleküls vermittelt die Bindungsfähigkeit an einzelsträngige Nucleinsäure. Die Phosphat-Gruppe sorgt für gute Wasserlöslichkeit der Verbindung 3.Compound 3 is named (Z) -5 - [[3-hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4- pyridinyl] methylene] -2-thioxo-4-thiazolidinone, or trivially named (Z) -5'-O-phosphono pyridoxylidene rhodanine. The rhodanine part of the molecule conveys the binding ability single-stranded nucleic acid. The phosphate group ensures good water solubility Connection 3.
Die Verbindung 3 unterliegt einer (Z/E)-Stereoisomerie zum (E)-Isomeren 4. Die Bindung an die
Kernbase Adenin unter Bildung eines Komplexes konnte wahrscheinlich gemacht werden.
Compound 3 undergoes a (Z / E) stereoisomerism to the (E) isomer 4. Binding to the core base adenine to form a complex could probably be made.
Die Analytik der Verbindung 3 umfaßt 1H-NMR-Spektroskopie, 13C-NMR-Spektroskopie,
31P-NMR-Spektroskopie, RP-18 HPLC, Fast Atom Bombardment Massenspektrometrie (FAB
MS), IR-Spektroskopie, UV-Spektrophotometrie und Fluoreszenzspektrophotometrie. Es folgen
typische analytische Daten der Verbindung 3:
C11 H11 N2 O6 P S2, M = 362.31 g/mol. FAB MS (MH+ berechnet für m/z 362.99): m/z (rel.Int.)
363.0 (12.0%, MH+), 227.4 (18.1%), 270.4 (8.7%), 171.2 (8.3%), 282.4 (7.1%), 267.1 (2.8%),
283.4 (2.1%), 265.1 (1.5%). 1H NMR (TFA-d): δ 2.91 (s, 3 H, 2'-CH3), 5.42 (d,|3J(31P,1H)| = 8.0
Hz, 2 H, 5'-CH2-OPO3H2), 7.76 (s, 1 H, 4'-CH), 8.47 (s, 1 H, 6-CH). 13C NMR, BB-entkoppelt
(TFA-d): δ 16.83 (s, 2'-CH3), 65.75 (s, 5'-CH2-OPO3H2), 121.04, 122.13 (2 s, C-4'), 133.34 (s,
C-6), 136.85, 136.91 (2 s, RR'C-SR''), 138.54 (s, C-5), 142.05 (s, C-4), 147.64 (s, C-2), 153.03 (s,
C-3), 171.93 (s, C = O), 193.39 (S, C = S). 31P NMR (TFA-d): δ - 4.24 (s, R-OPO3H2). UV/VIS
(H2O): λmax,1 = 300-304 nm [E (1%/1 cm) = 250-270], λmax,2 = 346-358 nm [E (1%/1 cm) =
380-410], λmax,3 = 446-450 nm [E (1%/1 cm) = 220-240].The analysis of compound 3 includes 1 H-NMR spectroscopy, 13 C-NMR spectroscopy, 31 P-NMR spectroscopy, RP-18 HPLC, Fast Atom Bombardment Mass Spectrometry (FAB MS), IR spectroscopy, UV spectrophotometry and fluorescence spectrophotometry . Typical analytical data of compound 3 follow:
C 11 H 11 N 2 O 6 PS 2 , M = 362.31 g / mol. FAB MS (MH + calculated for m / z 362.99): m / z (rel.Int.) 363.0 (12.0%, MH + ), 227.4 (18.1%), 270.4 (8.7%), 171.2 (8.3%), 282.4 (7.1%), 267.1 (2.8%), 283.4 (2.1%), 265.1 (1.5%). 1 H NMR (TFA-d): δ 2.91 (s, 3 H, 2'-CH 3 ), 5.42 (d, | 3 J ( 31 P, 1 H) | = 8.0 Hz, 2 H, 5'-CH 2 -OPO 3 H 2 ), 7.76 (s, 1 H, 4'-CH), 8.47 (s, 1 H, 6-CH). 13 C NMR, BB-decoupled (TFA-d): δ 16.83 (s, 2'-CH 3 ), 65.75 (s, 5'-CH 2 -OPO 3 H 2 ), 121.04, 122.13 (2 s, C- 4 '), 133.34 (s, C-6), 136.85, 136.91 (2 s, RR'C-SR''), 138.54 (s, C-5), 142.05 (s, C-4), 147.64 (s , C-2), 153.03 (s, C-3), 171.93 (s, C = O), 193.39 (S, C = S). 31 P NMR (TFA-d): δ - 4.24 (s, R-OPO 3 H 2 ). UV / VIS (H 2 O): λ max, 1 = 300-304 nm [E (1% / 1 cm) = 250-270], λ max, 2 = 346-358 nm [E (1% / 1 cm ) = 380-410], λ max, 3 = 446-450 nm [E (1% / 1 cm) = 220-240].
Man löst 3,83 g 2-Thioxo-4-thiazolidinon (Rhodanin) (M = 133,18 g/mol; n = 28,76 mmol) in 150 ml absolutem Ethanol in einem 50 ml NS29/32 Rundkolben mit Rückflußkühler und gibt 7,63 g Pyridoxal-5'-phosphat-monohydrat (M= 265,16 g/mol; n = 28,78 mmol) hinzu. Das Pyridoxal-5'- phosphat-monohydrat löst sich in der Kälte fast nicht.3.83 g of 2-thioxo-4-thiazolidinone (rhodanine) (M = 133.18 g / mol; n = 28.76 mmol) are dissolved in 150 ml of absolute ethanol in a 50 ml NS29 / 32 round bottom flask with reflux condenser and gives 7.63 g Pyridoxal-5'-phosphate monohydrate (M = 265.16 g / mol; n = 28.78 mmol) was added. The pyridoxal-5'- phosphate monohydrate almost does not dissolve in the cold.
Man kocht auf dem Wasserbad mit einem Siedesteinchen am Rückfluß. Das Pyridoxal-5'- phosphat-monohydrat geht nun langsam in Lösung und eine zunächst gelbe, dann orange, dann rote Suspension entsteht. Nach 20 min Sieden gibt man durch den Kühler 150 ml Wasser zu, weil die Suspension aufzustoßen beginnt. Man erwärmt noch 20 min, wobei das rote Reaktionsprodukt ausfällt und zum Aufstoßen führt. Danach kühlt man nicht mehr als 3 Stunden im Gefrierfach bei einer Temperatur von -18°C.You cook on the water bath with a boiling stone at reflux. The pyridoxal-5'- Phosphate monohydrate now slowly goes into solution and an initially yellow, then orange, then red suspension is formed. After boiling for 20 minutes, 150 ml of water are added through the cooler because the suspension begins to belch. The mixture is heated for a further 20 min, the red reaction product fails and leads to belching. After that, do not chill in the freezer for more than 3 hours a temperature of -18 ° C.
Auf diese Weise erhält man die zunächst orange (Z/E)-Mischform der Verbindung, in der das (Z)-Stereoisomer bei weitem überwiegt. Wenn lange bei Anwesenheit von Wasser gekühlt wird oder das orange (Z/E)-Produkt in Wasser länger aufgekocht wird, geht die orange Mischform ganz in das gelbe (Z)-Stereoisomer über.In this way, the initially orange (Z / E) mixed form of the compound is obtained, in which the (Z) stereoisomer by far outweighs. When cooling in the presence of water for a long time or the orange (Z / E) product is boiled in water for a longer time, the orange mixed form is completely gone into the yellow (Z) stereoisomer.
Das orange Produkt wird abgesaugt, mit der Mutterlauge überführt und mit 100 ml eiskaltem abs. Ethanol gewaschen. Vakuumtrocknung im Exsikkator über wfr. Calciumchlorid (CaCl2); Ausbeute: 9,5 g (91%, bezogen auf wasserfreie Substanz) orangegelbes, feinkristallines Pulver (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl)-4-pyridinyl]methylen]-2-thioxo-4- thiazolidinon, Gehalt w < 96% (1H-NMR, RP 18 - HPLC, bezogen auf wasserfreie und alkoholfreie Substanz), das Produkt enthält trotz Vakuumtrocknung Ethanol und Wasser.The orange product is filtered off, transferred with the mother liquor and with 100 ml of ice-cold abs. Washed ethanol. Vacuum drying in a desiccator over wfr. Calcium chloride (CaCl 2 ); Yield: 9.5 g (91%, based on anhydrous substance) of orange-yellow, finely crystalline powder (Z) -5 - [[3-hydroxy-2-methyl-5 - [(phosphonooxy) methyl) -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, content w <96% ( 1 H-NMR, RP 18 - HPLC, based on anhydrous and alcohol-free substance), the product contains ethanol and water despite vacuum drying.
Die Substanz 3 soll in radioaktiv markierter (32P oder 35S) Form als Sonde für einzelsträngige Nucleinsäure dienen. In radioactively labeled ( 32 P or 35 S) form, substance 3 is said to serve as a probe for single-stranded nucleic acid.
Die Substanz 3 soll in radioaktiv unmarkierter/markierter Form als Hilfsmittel für die elektrophoretische Trennung einzelsträngiger Nucleinsäure dienen.Substance 3 is said to be in radioactive, unlabelled / labeled form as an aid for serve electrophoretic separation of single-stranded nucleic acid.
Die nichtkovalent bindende Form 3 oder 4 in bezug auf einzelsträngige DNA kann durch
Bestrahlung mit UV-Licht der Wellenlänge 366 nm oder 254 nm photochemisch fixiert werden.
Dabei reagiert 3/4 mit einer Thymin-Kernbasen-Methylgruppe photochemisch unter Abspaltung
von Schwefelwasserstoff.
The noncovalently binding form 3 or 4 with respect to single-stranded DNA can be fixed photochemically by irradiation with UV light of the wavelength 366 nm or 254 nm. 3/4 reacts photochemically with a thymine core base methyl group with elimination of hydrogen sulfide.
Die Substanz 3 soll aufgrund seiner (Z/E)-Stereoisomerie als Hilfsmittel für die Fluoreszenzdetektion einzelsträngiger DNA dienen. Das (E)-Stereoisomer 4 fluoresziert in DMSO, das (Z)-Stereoisomer in Wasser wesentlich weniger. Angenommen wird, daß die an einzelsträngige DNA bindende Form das (E)-Stereoisomere 4 ist. Dadurch kann bei auftretender Fluoreszenz nach Extraktion mit DMSO einzelsträngige DNA nachgewiesen werden.Due to its (Z / E) stereoisomerism, substance 3 is said to be an aid for Fluorescence detection of single-stranded DNA are used. The (E) stereoisomer 4 fluoresces in DMSO, the (Z) stereoisomer in water, significantly less. It is assumed that the single-stranded DNA binding form that is (E) stereoisomer 4. This can result in Fluorescence can be detected after extraction with DMSO single-stranded DNA.
Die Substanz 3 soll als therapeutisches Hilfsmittel für die Beeinflussung von Vermehrungsvorgängen von infektiösen Erregern dienen, die im Wirt mit Zwischenstufen einzelsträngiger DNA ablaufen, z. B. Retroviren oder das Hepatitis-B-Virus.Substance 3 is said to be a therapeutic tool for influencing Propagation processes of infectious pathogens serve in the host with intermediate stages run single-stranded DNA, z. B. retroviruses or the hepatitis B virus.
Die (Z/E)-Stereoisomerie von 3 kann abhängig von der Temperatur (Thermochromie) und abhängig vom Lösungsmittel (Solvatochromie) auftreten. Daher kann 3 als Temperaturindikator und/oder Lösungsmittelindikator dienen.The (Z / E) stereoisomerism of 3 can depend on the temperature (thermochromism) and depending on the solvent (solvatochromism). Therefore 3 can be used as a temperature indicator and / or serve as a solvent indicator.
Die (Z/E)-Stereoisomerie von 3 gegenüber 4 kann abhängig vom Anlegen eines elektrischen Feldes auftreten (Elektrochromie). Daher kann 3 als digitales Schaltelement aufgrund der unterschiedlichen fluoreszenzspektrophotometrischen Eigenschaften von 3 gegenüber 4 z. B. bei der Anregung durch Laserlicht der Wellenlänge 480 nm dienen. Dabei tritt nach Anlegen eines elektrischen Feldes an 3 Umlagerung in 4 und damit Fluoreszenemission bei 575 nm durch Exzitation bei 480 nm auf.The (Z / E) stereoisomerism of 3 versus 4 can depend on the application of an electrical one Field (electrochromism). Therefore 3 can be used as a digital switching element due to the different fluorescence spectrophotometric properties of 3 versus 4 z. B. at serve for excitation by laser light with a wavelength of 480 nm. This occurs after creating a electric field at 3 rearrangement in 4 and thus fluorescence emission at 575 nm Excitation at 480 nm.
Die Verbindung 3 kann im Stoffwechsel als Antagonist des Coenzymes Pyridoxal-5'-phosphat wirken und deshalb eventuell tumorhemmende Eigenschaften aufweisen.Compound 3 can act as an antagonist of the coenzyme pyridoxal-5'-phosphate in metabolism act and therefore may have anti-tumor properties.
Die Verbindung 3 kann eventuell zur Proliferationskontrolle/Chemotherapie/Zytostasetherapie von malignen Tumoren in lokaler Applikation auf Hauttumore (malignes Melanom) in Verbindung mit UV-Bestrahlung dienen und/oder zur Proliferationskontrolle von anderen Hautkrankheiten mit erhöhter Zellteilungsrate dienen (z. B. Psoriasis). Dabei wird die Bindung an replikationsaktive einzelsträngige DNA-Bereiche durch UV-Bestrahlung photochemisch fixiert und führt zu lokal begrenzter Zytotoxizität.Compound 3 may be used for proliferation control / chemotherapy / cytostatic therapy of malignant tumors in local application on skin tumors (malignant melanoma) in Used in conjunction with UV radiation and / or for the proliferation control of others Skin diseases with an increased cell division rate serve (e.g. psoriasis). This binds to Replication-active single-stranded DNA areas fixed photochemically by UV irradiation and leads to localized cytotoxicity.
Claims (3)
1. (Z) -5 - [[3-hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone of the formula 3.
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19645974A DE19645974C1 (en) | 1996-11-07 | 1996-11-07 | (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use |
NZ335977A NZ335977A (en) | 1996-11-07 | 1997-11-07 | Pyridine derivatives which are knoevenagel condensation products |
BRPI9712930-5A BR9712930A (en) | 1996-11-07 | 1997-11-07 | knoevenagel condensation products, processes for their preparation and application |
TR1999/01733T TR199901733T2 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, their production method and use. |
HU9904289A HUP9904289A3 (en) | 1996-11-07 | 1997-11-07 | Pyridines substituted by heterocyclic groups, method for their production and pharmaceutical compositions containing the same |
IL12982697A IL129826A0 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products method for their production and their use |
PL97333128A PL333128A1 (en) | 1996-11-07 | 1997-11-07 | New products of knoevenagel's condensation, method of manufacturing of them and their applications |
CZ991609A CZ160999A3 (en) | 1996-11-07 | 1997-11-07 | Novel knoevenagel condensation products, processes of their preparation and their use |
PCT/EP1997/006184 WO1998020013A1 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
EP97951145A EP0937089A1 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
JP52107198A JP2001503752A (en) | 1996-11-07 | 1997-11-07 | Novel Knebena gel condensation product, its preparation and use |
AU54798/98A AU728345B2 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
SK617-99A SK61799A3 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
CA002270973A CA2270973A1 (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
KR1019990704073A KR20000053141A (en) | 1996-11-07 | 1997-11-07 | New knoevenagel condensation products, method for their production and their use |
CN97199496A CN1236369A (en) | 1996-11-07 | 1997-11-07 | New Knoevenagel condensation products, method for their production and use |
DE19819820A DE19819820A1 (en) | 1996-11-07 | 1998-05-04 | Mono-, oligo-, and polymeric Knoevenagel condensation products useful e.g. in pharmaceuticals, cosmetics and assay procedures |
NO992209A NO992209L (en) | 1996-11-07 | 1999-05-06 | New Knoevenagel condensation products, processes for their preparation and their use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19645974A DE19645974C1 (en) | 1996-11-07 | 1996-11-07 | (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19645974C1 true DE19645974C1 (en) | 1998-08-13 |
Family
ID=7810958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19645974A Expired - Fee Related DE19645974C1 (en) | 1996-11-07 | 1996-11-07 | (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0937089A1 (en) |
JP (1) | JP2001503752A (en) |
KR (1) | KR20000053141A (en) |
CN (1) | CN1236369A (en) |
AU (1) | AU728345B2 (en) |
BR (1) | BR9712930A (en) |
CA (1) | CA2270973A1 (en) |
CZ (1) | CZ160999A3 (en) |
DE (1) | DE19645974C1 (en) |
HU (1) | HUP9904289A3 (en) |
IL (1) | IL129826A0 (en) |
NO (1) | NO992209L (en) |
NZ (1) | NZ335977A (en) |
PL (1) | PL333128A1 (en) |
SK (1) | SK61799A3 (en) |
TR (1) | TR199901733T2 (en) |
WO (1) | WO1998020013A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0101890A2 (en) | 1998-05-04 | 2001-10-28 | Andreas Johannes Kesel | Monomeric, oligomeric and polymeric knoevenagel condensation products |
BR9913157A (en) * | 1998-08-21 | 2001-05-15 | Viropharma Inc | Processes for treating or preventing infection caused by at least one virus of the flaviviridae and diseases associated with said infection and infection caused by at least one virus of the genus hepacivirus of flavivirity and diseases associated with said infection, pharmaceutical composition to treat or prevent viral infections , it's composed |
IL146184A0 (en) * | 1999-04-30 | 2002-07-25 | Walter Oberthur | Antioxidative vitamin b6 analogs |
US20030071780A1 (en) * | 2001-10-16 | 2003-04-17 | Vincent Kent D. | High resolution display |
US6940497B2 (en) * | 2001-10-16 | 2005-09-06 | Hewlett-Packard Development Company, L.P. | Portable electronic reading apparatus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103776D0 (en) * | 1991-12-19 | 1991-12-19 | Astra Ab | NEW COMPOUNDS |
IT1266570B1 (en) * | 1993-07-30 | 1997-01-09 | Zambon Spa | DERIVATIVES OF PROPANAMIDE N-ETEROARYL SUBSTITUTES USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES |
FR2722790B1 (en) * | 1994-07-19 | 1996-10-04 | Roussel Uclaf | NOVEL CEPHALOSPORINS COMPRISING IN POSITION 7 A SUBSTITUTED RADICAL BENZYLOXYMINO, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
-
1996
- 1996-11-07 DE DE19645974A patent/DE19645974C1/en not_active Expired - Fee Related
-
1997
- 1997-11-07 CZ CZ991609A patent/CZ160999A3/en unknown
- 1997-11-07 WO PCT/EP1997/006184 patent/WO1998020013A1/en not_active Application Discontinuation
- 1997-11-07 BR BRPI9712930-5A patent/BR9712930A/en not_active IP Right Cessation
- 1997-11-07 JP JP52107198A patent/JP2001503752A/en active Pending
- 1997-11-07 PL PL97333128A patent/PL333128A1/en unknown
- 1997-11-07 TR TR1999/01733T patent/TR199901733T2/en unknown
- 1997-11-07 CA CA002270973A patent/CA2270973A1/en not_active Withdrawn
- 1997-11-07 SK SK617-99A patent/SK61799A3/en unknown
- 1997-11-07 IL IL12982697A patent/IL129826A0/en unknown
- 1997-11-07 CN CN97199496A patent/CN1236369A/en active Pending
- 1997-11-07 KR KR1019990704073A patent/KR20000053141A/en not_active Application Discontinuation
- 1997-11-07 NZ NZ335977A patent/NZ335977A/en unknown
- 1997-11-07 EP EP97951145A patent/EP0937089A1/en not_active Withdrawn
- 1997-11-07 AU AU54798/98A patent/AU728345B2/en not_active Revoked
- 1997-11-07 HU HU9904289A patent/HUP9904289A3/en unknown
-
1999
- 1999-05-06 NO NO992209A patent/NO992209L/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
Tetrahedron (1996), 52(47), 14787-14800 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001503752A (en) | 2001-03-21 |
TR199901733T2 (en) | 1999-09-21 |
HUP9904289A3 (en) | 2001-08-28 |
NO992209D0 (en) | 1999-05-06 |
NZ335977A (en) | 2000-12-22 |
IL129826A0 (en) | 2000-02-29 |
KR20000053141A (en) | 2000-08-25 |
AU728345B2 (en) | 2001-01-04 |
CA2270973A1 (en) | 1998-05-14 |
CN1236369A (en) | 1999-11-24 |
SK61799A3 (en) | 2000-01-18 |
PL333128A1 (en) | 1999-11-22 |
WO1998020013A1 (en) | 1998-05-14 |
AU5479898A (en) | 1998-05-29 |
CZ160999A3 (en) | 1999-09-15 |
NO992209L (en) | 1999-07-01 |
EP0937089A1 (en) | 1999-08-25 |
BR9712930A (en) | 2006-04-18 |
HUP9904289A2 (en) | 2001-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69925624T2 (en) | Nucleic Acid MARKING CONNECTIONS | |
DE2746942C2 (en) | ||
EP1001951B1 (en) | Thiazole derivatives, method for their production and use | |
EP0152459A1 (en) | Process for producing oligonucleotides. | |
EP0962497A1 (en) | Rhodamine derivates and their use in diagnostic systems | |
HUE033030T2 (en) | Crystalline minocycline base and processes for its preparation | |
US4398031A (en) | Coumarin derivatives and method for synthesizing 5'-methyl psoralens therefrom | |
Golankiewicz et al. | Methylation of desmethyl analogue of Y nucleosides. Wyosine from guanosine | |
DE1620694C3 (en) | Process for the preparation of 5-methyl-7-diethylamino-s-triazolo [1,5-a] pyrimidine and its salts with acids | |
DE19645974C1 (en) | (Z) -5 - [[3-Hydroxy-2-methyl-5 - [(phosphonooxy) methyl] -4-pyridinyl] methylene] -2-thioxo-4-thiazolidinone, process for its preparation and use | |
DE3834861A1 (en) | ARYLALKOXYCUMARINE, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM | |
DE4213703A1 (en) | Fluorescence-labeled compounds, their production and use | |
EP0901501B1 (en) | Nucleoside derivatives with photo-unstable protective groups | |
Nair et al. | Chemistry of 1, 5-diazapentadienium (vinamidinium) salts: alkylation reactions to multifunctional dienamines and dienaminones | |
DE60125958T2 (en) | REAGENTS FOR THE DETERMINATION OF ATOMIC OXYGEN | |
EP0578067A1 (en) | Photochemical labeling of nucleic acids with europium-chelating reagents and their use in gene probe systems | |
Hosmane et al. | Chemical modification of nucleic acid components: reactions of cytosine, cytidine, isocytosine, and adenine with methyl N-cyanomethanimidate | |
Shaw et al. | 3-Ureidoacrylonitriles: Novel products from the photoisomerization of cytosine, 5-methylcytosine, and related compounds | |
EP1401851B1 (en) | Two-stage protective groups for the synthesis of biopolymers | |
CN100360534C (en) | Separation of regioisomers of metal phthalocyanines | |
Wu et al. | Alkaloids of Thalictrum XXXIV. Three new alkaloids, Thalmirabine, Thalistine, and O-Methylthalibrine, and others from roots of Thalictrum minus Race B | |
JPS5943960B2 (en) | New saponin substance | |
Hussain et al. | Khyberine and the biogenesis of dimeric aporphine-benzylisqoquinoline alkaloids | |
CN107488144B (en) | Molecule capable of specifically binding and inhibiting Tau protein aggregation and preparation method and application thereof | |
WO1998020013A9 (en) | New knoevenagel condensation products, method for their production and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8100 | Publication of patent without earlier publication of application | ||
D1 | Grant (no unexamined application published) patent law 81 | ||
8364 | No opposition during term of opposition | ||
AG | Has addition no. |
Ref country code: DE Ref document number: 19819820 Format of ref document f/p: P |
|
8339 | Ceased/non-payment of the annual fee |